HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
HERON THERAPEUTICS, INC. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.36−0.00 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
HERON THERAPEUTICS, INC. /DE/ revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CINVANTI | $89.20M | $91.55M | $96.76M | $100.71M | $99.42M | $100.21M | $100.08M | $97.48M | $98.08M | $97.63M | $94.87M | $93.67M | 59.0% | -10.3% |
| ZYNRELEF | $43.13M | $40.27M | $38.07M | $34.00M | $30.93M | $28.58M | $25.55M | $22.78M | $20.91M | $19.21M | $17.73M | $15.94M | 28.5% | +39.4% |
| APONVIE | $14.52M | $12.71M | $11.57M | $9.69M | $7.80M | $6.35M | $4.52M | $3.06M | $2.27M | $1.57M | $1.39M | – | 9.6% | +86.2% |
| SUSTOL | $4.33M | $6.19M | $8.50M | $10.69M | $11.55M | $13.39M | $14.14M | $14.42M | $15.10M | $13.69M | $13.06M | $12.31M | 2.9% | -62.5% |
By region
From the segment and revenue-disaggregation notes of Heron Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.